ArticleProceedings of the National Academy of Sciences of the United States of America2020
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Lutetium-177 radiopharmaceuticals in cancer care: progress and challenges.Frontiers in pharmacology · 2026Review
- Inhibition of Growth and Induction of Apoptosis of Human Prostate Cancer Cells by Enzymatic Blockage of Kallikreins.Prostate cancer · 2026Article
- PSMA-targeted radioligand therapy in advanced prostate cancer: a narrative review of ^177Lu-PSMA, emerging ^225Ac-PSMA strategies, and therapeutic sequencing.Oncology reviews · 2026Review
- Alpha Particle Emitter Radiolabeled Antibodies in Cancer Therapy: Current Status, Challenges, and Future Prospects.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Astatine-211 and actinium-225: two promising nuclides in targeted alpha therapy.Acta biochimica et biophysica Sinica · 2024Review
- Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies.Cancers · 2024Review
- Engineered Antibodies as Cancer Radiotheranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Review
- Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics · 2024Review
- Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response.Molecular cancer research : MCR · 2023Article
- The application of radionuclide therapy for breast cancer.Frontiers in nuclear medicine · 2023Review
- A pulmonologist's guide to perform and analyse cross-species single lung cell transcriptomics.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Antibody Engineering for Nuclear Imaging and Radioimmunotherapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- HBioconjugate chemistry · 2022Article
- Exosomes as A Next-Generation Diagnostic and Therapeutic Tool in Prostate Cancer.International journal of molecular sciences · 2021Review
- Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".Pharmaceutics · 2021Review
- PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Perspectives on metals-based radioimmunotherapy (RIT): moving forward.Theranostics · 2021Review
- Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 4 countries.
Mesude BicakDepartment of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genome Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0002-4546-9801
Katharina LückerathDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095.ORCID 0000-0001-6109-2066
Teja KalidindiDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0002-0210-0270
Michael E PhelpsDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095; michaelephelpsphd@gmail.com Robert.klein@mssm.edu hulmert@mednet.ucla.edu.
Sven-Erik StrandDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, 223 81 Lund, Sweden.
Michael J MorrisGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Caius G RaduDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095.ORCID 0000-0002-9338-5397
Robert DamoiseauxDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095.
Mari T PeltolaDepartment of Biochemistry-Biotechnology, University of Turku, FI-20014 Turun yliopisto, Finland.ORCID 0000-0002-8615-0231
Norbert PeekhausDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095.ORCID 0000-0001-9584-4879
Austin HoDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095.ORCID 0000-0001-6016-9236
Darren VeachDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0002-8201-622X
Ann-Christin Malmborg HagerDiaprost AB, 223 63 Lund, Sweden.ORCID 0000-0003-4619-8529
Steven M LarsonDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Hans LiljaGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0001-5871-7846
Michael R McDevittDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Robert J KleinDepartment of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genome Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029; michaelephelpsphd@gmail.com Robert.klein@mssm.edu hulmert@mednet.ucla.edu.
David UlmertDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095; michaelephelpsphd@gmail.com Robert.klein@mssm.edu hulmert@mednet.ucla.edu.
University of California, Los Angeles · USMemorial Sloan Kettering Cancer Center · USIcahn School of Medicine at Mount Sinai · USLund University · SEUniversity of Turku · FI
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MWomen's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0MUCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6MTumor Evolution and Changes in MetabolismP50CA086438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LARSON, STEVEN MARK · 2000 to 2015
$29.9MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2MTREATMENT OF CANCER PATIENTS WITH THYMIC FACTORSP01CA033049 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LARSON, STEVEN MARK · 1985 to 2009
$19.8MRECOMBINANT ANTICD33 ANTIBODY FOR AMLR01CA055349 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SCHEINBERG, DAVID A · 1991 to 2020
$6.8MImproving prostate cancer screening by integration of SNPs with blood biomarkersR01CA175491 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KLEIN, ROBERT J. · 2013 to 2018
$2.8MProspective validation of a multi-marker prostate cancer prediction modelR01CA160816 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BOORJIAN, STEPHEN, COOPERBERG, MATTHEW R · 2012 to 2015
$1.9MImproving therapy of glioblastoma multiforme by enhancing therapeutic drug deliveR01CA166078 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI MCDEVITT, MICHAEL R. · 2012 to 2015
$1.3MNanoSPECT/CT for Oncology ResearchS10RR028889 · NCRR · SLOAN-KETTERING INST CAN RESEARCH · PI ZANZONICO, PAT B · 2011 to 2011
$907kNCI NIH HHS F31 CA167863NCI NIH HHS P01 CA033049NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA086438NCI NIH HHS P50 CA092131NCI NIH HHS P50 CA092629NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA055349NCI NIH HHS R01 CA160816NCI NIH HHS R01 CA166078NCI NIH HHS R01 CA175491NCRR NIH HHS S10 RR020892NCRR NIH HHS S10 RR028889
Abstract
Hu11B6 is a monoclonal antibody that internalizes in cells expressing androgen receptor (AR)-regulated prostate-specific enzyme human kallikrein-related peptidase 2 (hK2;
Indexed as
ActiniumAlpha ParticlesAnimalsBiomarkers, TumorHumansImmunoconjugatesMaleMiceMice, NudeNeoplasms, ExperimentalProstate-Specific AntigenProstatic NeoplasmsTissue KallikreinsActiniumActinium-225Biomarkers, TumorImmunoconjugatesProstate-Specific AntigenTissue Kallikreins225AchK2hu11B6prostate cancerradiommunotherapy
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.